Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
  • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
  • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/35—Valency
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/52—Constant or Fc region; Isotype
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/55—Fab or Fab'
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
  • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
  • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
  • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Definitions

• antibody-based therapeutics are being developed for a variety of uses, e.g., for treating various diseases or conditions.
• antibody-based therapeutics may need to be tuned so that they have desirable characteristics (for example, desirable biodistribution, half-lives, etc.) after administration to a subject.
• Some antibody-based therapeutics have a format that differs from that of a native immunoglobulin molecule.
• an antibody or antibody fragment is fused to another polypeptide; in some, the antibody or antibody fragment(s) is in a configuration or has a valence not found in nature.
• These antibody-based therapeutics may also need to be tuned.
• the present invention addresses this need with the provision of self-assembled polypeptide complexes comprising (a) fusion polypeptides (1) comprising Fc polypeptides and (2) a nanocage monomer or subunit thereof and (b) fusion polypeptides (1) comprising an antibody fragment and (2) a nanocage monomer or subunit thereof.
• the Fc polypeptides comprise certain amino acid residues at particular positions.
• fusion polypeptides comprising: (1) an Fc polypeptide and (2) a nanocage monomer or subunit thereof, wherein the Fc polypeptide comprises an IgG1 Fc chain, wherein said IgG1 Fc chain comprises (1) an amino acid residue other than glycine at position 237 and (2) a proline residue at position 329, according to EU numbering.
• the nanocage monomer or subunit thereof is a ferritin monomer or subunit thereof.
• the ferritin monomer or subunit thereof is a ferritin light chain or subunit thereof.
• the ferritin monomer or subunit thereof is a human ferritin or subunit thereof.
• the ferritin monomer or subunit thereof is a ferritin monomer subunit, e.g., a C-half ferritin.
• the Fc polypeptide is linked to the C-half ferritin’s N-terminus, e.g., via an amino acid linker.
• the amino acid linker comprises a (G n S) m linker, e.g., a (GGGGS) m (SEQ ID NO:19) linker.
• the Fc polypeptide comprises a single chain Fc (scFc) comprising two Fc chains, wherein the two Fc chains are linked via an amino acid linker, e.g., a (G n S) m linker, e.g., a (GGGGS) m (SEQ ID NO:19) linker.
• the Fc polypeptide comprises an IgG1 Fc chain.
• the IgG1 Fc chain comprises an alanine at position 237 according to EU numbering.
• the IgG1 Fc chain comprises: an alanine at position 234, an alanine at position 235, an arginine at position 236, and a leucine at position 330, according to EU numbering.
• self-assembled polypeptide complexes comprising: (a) a plurality of first fusion polypeptides, each first fusion polypeptide being a fusion polypeptide of any one of claims 1-16, and (b) a plurality of second fusion polypeptides, each second fusion polypeptide comprising (1) an antigen-binding antibody fragment and a (2) a nanocage monomer or subunit thereof.
• the nanocage monomer or subunit thereof of each second fusion polypeptide is a ferritin monomer or subunit thereof.
• the ferritin monomer or subunit thereof is a ferritin light chain or subunit thereof.
• the ferritin monomer or subunit thereof is a human ferritin or subunit thereof.
• the self-assembled polypeptide complex does not comprise any ferritin heavy chains or subunits of ferritin heavy chains.
• the antigen-binding antibody fragment is linked to the nanocage monomer or subunit thereof via an amino acid linker, e.g., an amino acid linker comprising a (G n S) m linker, e.g., a (GGGGS) m (SEQ ID NO:19) linker.
• an amino acid linker e.g., an amino acid linker comprising a (G n S) m linker, e.g., a (GGGGS) m (SEQ ID NO:19) linker.
• the antigen-binding antibody fragment of each second fusion polypeptide is linked to the N-terminus of nanocage monomer or subunit thereof.
• the antigen-binding antibody fragment of each second fusion polypeptide is a Fab fragment.
• each second fusion polypeptide does not comprise any antibody CH2 or CH3 domains.
• the self-assembled polypeptide complex further comprises a plurality of third fusion polypeptides, each third fusion polypeptide comprising (1) an antigen-binding antibody fragment and (2) a nanocage monomer or a subunit thereof, wherein the third fusion polypeptide is different than the second fusion polypeptide.
• the antigen-binding antibody fragment of each third fusion polypeptide is a Fab fragment.
• each third fusion polypeptide does not comprise any antibody CH2 or CH3 domains.
• each first fusion polypeptide and each second fusion polypeptide is a ferritin monomer subunit, and a. each first fusion polypeptide comprises a C-half-ferritin, and each second fusion polypeptide comprises a N-half-ferritin; or b. each first fusion polypeptide comprises an N-half ferritin, and each second fusion polypeptide comprises a C-half-ferritin.
• the self-assembled polypeptide complex is characterized by a 1:1 ratio of first fusion polypeptides to second fusion polypeptides.
• the self-assembled polypeptide complex comprises a total of 24 to 48 fusion polypeptides. In some embodiments, the self-assembled polypeptide complex comprises a total of least 24 fusion polypeptides. [0029] In some embodiments, the self-assembled polypeptide complex comprises a total of at least 32 fusion polypeptides. [0030] In some embodiments, the self-assembled polypeptide complex has a total of about 32 fusion polypeptides. [0031] In some embodiments, the self-assembled polypeptide complex exhibits no binding to at least one human Fc ⁇ receptor, as determined in an in vitro assay.
• the self-assembled polypeptide complex exhibits no binding to one or more human Fc ⁇ receptors selected from the group consisting of hFc ⁇ RI, hFc ⁇ RIIa, hFc ⁇ RIIb, hFc ⁇ RIIIa, hFc ⁇ RIIIb, and combinations thereof, as determined in an in vitro assay.
• the self-assembled polypeptide complex exhibits no binding to hFc ⁇ RI, as determined in an in vitro assay.
• the self-assembled polypeptide complex exhibits no binding to hFc ⁇ RIIa, as determined in an in vitro assay.
• the self-assembled polypeptide complex exhibits no binding to hFc ⁇ RIIIa, as determined in an in vitro assay. In some embodiments, the self-assembled polypeptide complex exhibits no binding to hFc ⁇ RIIb, as determined in an in vitro assay. In some embodiments, the self-assembled polypeptide complex exhibits no binding to hFc ⁇ RIIIb, as determined in an in vitro assay.
• self-assembled polypeptide complexes comprising: (a) a plurality of first fusion polypeptides, each first fusion polypeptide comprising (1) a scFc and (2) a ferritin monomer or subunit thereof, and (b) a plurality of second fusion polypeptides, each second fusion polypeptide comprising (1) an antigen-binding antibody fragment linked to (2) a ferritin monomer or subunit thereof, wherein the scFc comprises two IgG1 Fc chains, each IgG1 Fc chain comprising: an alanine at position 234, an alanine at position 235, an arginine at position 236, an alanine at position 237, a proline at position 329, and a leucine at position 330, according to EU numbering.
• each first fusion polypeptide comprises a C-half-ferritin, and each second fusion polypeptide comprises an N-half-ferritin; or b. each first fusion polypeptide comprises an N-half ferritin, and each second fusion polypeptide comprises a C-half-ferritin.
• each first fusion polypeptide comprises a scFc linked to the C-half-ferritin’s N-terminus, and each second fusion polypeptide comprises a Fab linked to the N-half-ferritin’s N-terminus.
• the self-assembled polypeptide complex is characterized by a 1:1 ratio of first fusion polypeptides to second fusion polypeptides.
• the self-assembled polypeptide complex further comprises a plurality of third fusion polypeptides, each third fusion polypeptide comprising (1) an antigen-binding antibody fragment linked to (2) a nanocage monomer or a subunit thereof, wherein the third fusion polypeptide is different than the second fusion polypeptide.
• the self-assembled polypeptide complex comprises a total of 24 to 48 fusion polypeptides.
• the self-assembled polypeptide complex comprises a total of least 24 fusion polypeptides.
• the self-assembled polypeptide complex comprises a total of at least 32 fusion polypeptides.
• the self-assembled polypeptide complex has a total of about 32 fusion polypeptides.
• the antibody-binding fragment is capable of binding to a tumor-associated antigen or an antigen associated with an autoimmune disorder.
• methods comprising administering a composition comprising the self-assembled polypeptide complex of any one of claims 17-54 to a mammalian subject.
• the subject is human.
• the subject has or is at risk of developing cancer.
• the subject has or is at risk of developing an autoimmune disorder.
• the method comprises administration by a systemic route.
• the systemic route comprises subcutaneous, intravenous, or intramuscular injection, inhalation, or intranasal administration.
• a composition comprising the self-assembled polypeptide complex described herein for administration to a mammalian subject.
• the subject is human.
• the subject has or is at risk of developing cancer.
• the subject has or is at risk of developing an autoimmune disorder.
• the composition is for administration by a systemic route.
• the systemic route comprises subcutaneous, intravenous, or intramuscular injection, inhalation, or intranasal administration.
• compositions comprising the self-assembled polypeptide complex described herein for use in administration to a mammalian subject.
• the subject is human.
• the subject has or is at risk of developing cancer.
• the subject has or is at risk of developing an autoimmune disorder.
• the compositions are for administration by a systemic route.
• the systemic route comprises subcutaneous, intravenous, or intramuscular injection, inhalation, or intranasal administration.
• FIG.1A is a diagrammatic representation of human ferritin light chain (hFTL) and exemplary N-half ferritin (N-hFTL) and C-half ferritin (C-hFTL) molecules.
• FIG.1B is a diagrammatic representation of fusion polypeptides that together form exemplary Multabodies of the disclosure.
• FIGs.2A, 2B, 2C, 2D, and 2E depict biolayer interferometry (BLI) time-response curves for the binding of a DR5-targeting Multabody (Cona MB IgG1 LLRAL) to human DR5, human DR4, human osteoprotegerin (OPG), human decoy receptor 1 (DcR1), and human DcR2, respectively.
• FIG.3 depicts exemplary BLI time-response curves for the binding of DR5- targeting Multabodies containing various Fc chains to human, cynomolgus monkey, and mouse FcRns, measured at pH 6.0 for association and pH 7.4 for dissociation.
• FIG.4 illustrates the dose-dependent killing of cancer cells by Cona MB IgG1 wt, Cona MB IgG1 LLRAL, and conatumumab (Cona) in different human tumor cell lines, quantified and represented as the percentage viable cells following Multabody or antibody treatment to vehicle-treated tumor cells.
• FIG.5A is a schematic illustrating the designs of pharmacokinetic studies described in Example 6.
• FIG.5B depict plots showing the plasma levels of Cona MB IgG1 wt, Cona MB IgG1 LLRAL, or conatumumab (Cona) following a single intraperitoneal (i.p.) or intravenous (i.v.) dose administered to severe combined immunodeficiency (SCID) mice.
• FIG.5C illustrates plasma levels of Cona MB IgG1 LLRAL or conatumumab in SCID mice administered with two i.p. doses, 96 hours apart.
• FIG.6A is a schematic that illustrates the design of an in vivo efficacy experiment described in Example 7 and conducted in a COLO 205 xenograft mouse model.
• FIG.6B and 6C show tumor volumes at various timepoints (FIG.6B) and on Day 88 (FIG.6C) in mice bearing COLO 205 xenograft tumors and treated with vehicle, conatumumab, or Cona MB IgG1 LLRAL.
• FIGs.6D-6G shows tumor growth curves for individual COLO 205 xenograft tumor-bearing mice treated with vehicle (FIG.6D), conatumumab (FIG.6E), or Cona MB IgG1 LLRAL (FIGs.6F and 6G).
• FIG.6H is a time plot that depicts plasma levels of Cona MB IgG1 LLRAL or conatumumab following i.p. administration to COLO 205 xenograft tumor-bearing mice.
• FIG.7A is a plot that depicts tumor volumes of mice in various groups over time following the first dose. “MB” indicates the Cona MB IgG1 LLRAL group. The triangles on the x-axis denote the treatment time points.
• FIGs.7B-7F show the tumor volumes of individual mice within the vehicle (FIG.7B) and 5 mg/kg, 1 mg/kg, 0.25 mg/kg, and 0.1 mg/kg Cona MB IgG1 LLRAL treatment (FIG.7C, FIG.7D, FIG.7E, and FIG.7F, respectively) groups.
• FIGs.7B-7F “CR” denotes complete regression.
• FIG.7G is a plot that depicts that amount of Cona MB IgG1 LLRAL detectable in blood samples collected at various timepoints after the first dose was administered.
• FIG.8 is a schematic depicting the design of a study of large tumor penetration and apoptosis induction by a DR5-targeting Multabody in an COLO 205 xenograft mouse model. Experiments are described in Example 9.
• FIGs.9A-9D depict representative tumor sections from mice that were untreated (FIGs.9A and 9C) or treated with a DR5-targeting Multabody (“MB”) (FIGs.9B and 9D). Sections were stained with an antibody against cleaved caspase-3, a marker of apoptosis. Experiments are described in Example 9. DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION Definitions [0072] The terms “about” and “approximately,” when used herein in reference to a value, are used interchangeably and refer to a value that is similar to the referenced value.
• the terms “about” and “approximately” may encompass a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the referred value.
• the terms “alter,” “altered,” “decrease,” “decreased,” “increase,” “increased,” or “reduction,” “reduced,” have meanings relative to a reference level.
• the reference level is a level known or as determined with an IgG that does not contain the referenced mutation(s) in the Fc region.
• binding refers to a non- covalent association between or among two or more entities.
• Binding between two or more entities can typically be assessed in any of a variety of contexts--including where interacting entities or moieties are studied in isolation or in the context of more complex systems (e.g., while covalently or otherwise associated with a carrier entity and/or in a biological system or cell).
• non-binding or “no binding,” or similar phrases, between two entities refers to 1) a lack of detectable binding or 2) binding below a set threshold that corresponds to no binding in an appropriate assay, e.g., an in vitro binding assay such as biolayer interferometry.
• a maximal association binding response of less than 0.1 nm after 180 seconds to a biosensor loaded with 0.8 nm of target when the test article is present at a concentration of 20 nM is classified as “non-binding.”
• the terms “ferritin” and “apoferritin” are used interchangeably herein and generally refer to a polypeptide (e.g., a ferritin chain) that is capable of assembling into a ferritin complex which typically comprises 24 protein subunits.
• the ferritin is a human ferritin, e.g., a human ferritin light chain, e.g., a human ferritin light chain having at least 85% sequence identity to SEQ ID NO:1 or UniProt P02792.
• the ferritin is a wild-type ferritin.
• the ferritin may be a wild-type human ferritin.
• the term “ferritin monomer,” is used herein to refer to a single chain of a ferritin that, in the presence of other ferritin chains, is capable of self-assembling into a polypeptide complex comprising a plurality of ferritin chains, e.g., 24 or more ferritin chains.
• linker is used to refer to an entity that connects two or more elements to form a multi-element agent.
• a polypeptide e.g., fusion polypeptide
• a polypeptide comprising a linker element has an overall structure of the general form S1-L-S2, wherein S1 and S2 may be the same or different and represent two domains associated with one another by the linker (L).
• the linker is an “amino acid linker,” that is, it comprises amino acid residues, e.g., an amino acid linker may comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acid residues.
• a linker is characterized in that it tends not to adopt a rigid three-dimensional structure, but rather provides flexibility to the polypeptide.
• multispecific refers to the characteristic of having at least two binding sites at which at least two different binding partners, e.g., an antigen or receptor (e.g., Fc receptor), can bind.
• an antigen or receptor e.g., Fc receptor
• a polypeptide complex that comprises at least two Fab fragments, wherein each of the two Fab fragments is capable of binding to a different antigen is “multispecific.”
• a polypeptide complex that comprises an Fc fragment (which is capable of binding to an Fc receptor) and a Fab fragment (which is capable of binding to an antigen) is “multispecific.”
• multivalent refers to the characteristic of having at least two binding sites at which a binding partner, e.g., an antigen or receptor (e.g., Fc receptor), can bind.
• the binding partners that can bind to at least two binding sites may be the same or different.
• the term “nanocage monomer,” as used herein, refers to a single chain of a polypeptide that is capable of self-assembling with other nanocage monomers to form a self- assembled polypeptide complex comprising a plurality of nanocage monomers.
• the nanocage monomer is selected from monomers of ferritin, apoferritin, encapsulin, sulfur oxygenase reductase (SOR), lumazine synthase, pyruvate dehydrogenase, carboxysome, vault proteins, GroEL, heat shock protein, E2P coat protein, MS2 coat protein, fragments thereof, and variants thereof.
• polypeptide generally has its art-recognized meaning of a polymer of at least three amino acids, e.g., linked to each other by peptide bonds.
• polypeptide is intended to be sufficiently general as to encompass not only polypeptides having a complete sequence recited herein, but also to encompass polypeptides that represent functional fragments (i.e., fragments retaining at least one activity) of such complete polypeptides.
• protein sequences generally tolerate some substitution without destroying activity.
• Polypeptides may contain L-amino acids, D-amino acids, or both and may contain any of a variety of amino acid modifications or analogs known in the art.
• proteins may comprise natural amino acids, non-natural amino acids, synthetic amino acids, and combinations thereof [0082]
• self-assembled when used in reference to a macromolecular complex (e.g., a polypeptide complex), refers to the spontaneous formation of that complex when sufficient constituents of the complex (e.g., fusion polypeptides) to be formed are present.
• complexes self-assemble in physiological conditions, or in a buffer (e.g., a solution) that corresponds to physiological conditions.
• a subject to an organism, typically a mammal (e.g., a human).
• a subject is suffering from or susceptible to a relevant disease, disorder or condition.
• a subject displays one or more symptoms or characteristics of a disease, disorder or condition.
• a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition.
• a subject is a patient.
• a subject is a subject to whom diagnosis and/or therapy is and/or has been administered.
• treatment refers to any administration of a therapy that partially or completely alleviates, ameliorates, relieves, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms, features, and/or causes of a particular disease, disorder, and/or condition.
• such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition.
• such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition.
• treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition. In some embodiments, treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.
• susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.
• the term “tumor-associated antigenor “tumor associated antigen” means an antigen that is present on tumor cells at a significantly greater amount than on normal cells.
• fusion polypeptides compatible with compositions and methods disclosed herein generally comprise a nanocage monomer or subunit thereof linked to either an Fc polypeptide or to an antigen-binding antibody fragment.
• the Fc polypeptide or the antigen-binding antibody fragment may be linked to the nanocage monomer or subunit thereof at a particular terminus of the nanocage monomer or subunit thereof, e.g., the N-terminus or the C-terminus.
• the Fc polypeptide or antigen-binding antibody fragment is linked via an amino acid linker, such as a linker as described herein. 1.
• Nanocage monomers and subunits thereof [0087]
• the nanocage monomer is a ferritin monomer.
• ferritin monomer is used herein to refer to a single chain of a ferritin that, in the presence of other ferritin chains, is capable of self-assembling into a polypeptide complex comprising a plurality of ferritin chains, e.g., 24 or more ferritin chains.
• the ferritin monomer is a ferritin light chain.
• the ferritin monomer does not include a ferritin heavy chain or other ferritin components capable of binding to iron or capable of ferroxidase activity.
• each fusion polypeptide within the self-assembled polypeptide complex comprises a ferritin light chain or a subunit of a ferritin light chain.
• the self-assembled polypeptide complex does not comprise any ferritin heavy chains or subunits of ferritin heavy chains.
• the ferritin monomer is a human ferritin chain, e.g., a human ferritin light chain, e.g., a human ferritin light chain having the sequence of at least residues 2-175 of SEQ ID NO:1.
• a “subunit” of a ferritin monomer refers to a portion of a ferritin monomer that is capable of spontaneously associating with another, distinct subunit of a ferritin monomer, so that the subunits together form a ferritin monomer, which ferritin monomer, in turn, is capable of self-assembling with other ferritin monomers to form a polypeptide complex.
• the ferritin monomer subunit comprises approximately half of a ferritin monomer.
• the term “N-half ferritin” refers to approximately half of a ferritin chain, which half comprises the N-terminus of the ferritin chain.
• C-half ferritin refers to approximately half a ferritin chain, which half comprises the C-terminus of the ferritin chain.
• the exact point at which a ferritin chain may be divided to form the N-half ferritin and the C-half ferritin may vary depending on the embodiment.
• the halves may be divided at a point that corresponds to a position between about position 75 to about position 100 of SEQ ID NO:1 (or a substantial portion thereof).
• an N-half ferritin based on a human ferritin light chain has an amino acid sequence corresponding to residues 1-95 of SEQ ID NO: 1 (or a substantial portion thereof, e.g., residues 2-95 of SEQ ID NO: 1)
• a C-half ferritin based on a human ferritin light chain has an amino acid sequence corresponding to residues 96-175 of SEQ ID NO: 1 (or a substantial portion thereof).
• the halves are divided at a point that corresponds to a position between about position 85 to about position 92 of SEQ ID NO: 1.
• an N-half ferritin based on a human ferritin light chain has an amino acid sequence corresponding to residues 1-90 of SEQ ID NO:1 (or a substantial portion thereof, e.g., residues 2-90 of SEQ ID NO: 1)
• a C-half ferritin based on a human ferritin light chain has an amino acid sequence corresponding to residues 91-175 of SEQ ID NO:1 (or a substantial portion thereof.
• Fc polypeptides [0094]
• fragment crystallizable (Fc) polypeptides comprise Fc chains that each have one or more mutations relative to a reference Fc chain of the same Ig class.
• the reference Fc chain may be of, e.g., the IgG1 class.
• numbering of residues within an antibody fragment, e.g., an Fc chain, throughout this disclosure is according to the EU numbering.
• the Fc polypeptide comprises one or more human IgG1 Fc chains that is, except for mutations noted herein, the Fc polypeptide comprises an Fc chain that is substantially similar to that of the Fc chains within a wild type human IgG1.
• the Fc polypeptide comprises one or more IgG1 Fc chains (e.g., human IgG1 Fc chains or a human Fc chains), that is, except for having particular residue(s) (which may be different than the residue(s) in the corresponding wild type Fc chains) at certain positions as noted herein, the Fc polypeptide comprises an Fc chain that has an amino acid sequence that is substantially similar to that of the chains within a wild type IgG1 Fc.
• the wild type IgG1 Fc is a human IgG1 Fc, in which each Fc chain has an amino acid sequence of SEQ ID NO:4.
• an Fc polypeptide may comprise an Fc chain with an amino acid sequence that is at least 85%, at least 87.5%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to that of an Fc chain within a wild-type IgG1 Fc.
• an Fc polypeptide comprises an Fc chain that comprises the particular residue(s) at certain position(s) specifically described for that Fc chain, but has an amino acid sequence that is otherwise 100% identical to a corresponding Fc chain within a wild type Fc chain, e.g., wild type IgG1 Fc chain.
• the Fc polypeptide comprises an Fc chain that has an amino acid sequence that differs by at least one, at least two, at least three, or at least four amino acid residues from the sequence of SEQ ID NO:4. In some embodiments, the Fc polypeptide comprises an Fc chain that has an amino acid sequence that differs by no more than ten, no more than nine, no more than eight, no more than seven, no more than six, no more than five, or no more than four amino acid residues from the sequence of SEQ ID NO:4. [0098] In some embodiments, the Fc polypeptide is a single chain Fc (scFc), which comprises two Fc chains linked together by a covalent linker, e.g., via an amino acid linker.
• scFc single chain Fc
• the Fc chain comprises (1) an amino acid residue other than glycine at position 237; and (2) a proline residue at position 329. In some embodiments, the Fc chain comprises an alanine at position 237. [0100] In some embodiments, the Fc chain is an IgG1 Fc chain and further comprises a mutation or set of mutations at one or more positions selected from position 234, position 235, position 236, position 330, and combinations thereof.
• the Fc chain is an IgG1 Fc chain that comprises an alanine at position 234, an alanine at position 235, an arginine at position 236, an alanine at position 237, a proline at position 329, and a leucine at position 330.
• the Fc chain further comprises a mutation at a position associated with glycosylation, e.g., position 297 (e.g., by comprising a glutamine at position 297).
• the Fc chain comprises a mutation or set of mutations (relative to a corresponding wild type Fc chain) associated with an altered characteristic as further described herein.
• the altered characteristic e.g., binding to an Fc receptor (e.g., an Fc ⁇ receptor or an FcRn)
• the altered characteristic comprises altered binding to an Fc receptor.
• the altered characteristic comprising altered binding to an Fc ⁇ receptor, e.g., a human Fc ⁇ R.
• the Fc ⁇ R is a human Fc ⁇ R selected from the group consisting of hFc ⁇ RI, hFc ⁇ RIIa, hFc ⁇ RIIb, hFc ⁇ RIIIa, hFc ⁇ RIIIb, and combinations thereof.
• the altered binding comprises no binding, or significantly reduced binding, relative to a corresponding control (e.g., binding levels typically observed under similar circumstances with a corresponding wild type chain), in an assay, e.g., an in vitro assay. 3.
• the antibody fragment is capable of binding to a tumor- associated antigen or an antigen associated with an autoimmune disorder.
• the antibody fragment is a Fab.
• the antibody fragment is a single-chain Fab (scFab); for example, a fusion polypeptide comprising both the heavy and light chains of a Fab, optionally linked by a linker (e.g., amino acid linker as disclosed herein) is used.
• the antibody fragment comprises a heavy chain variable region (e.g., a VH).
• the antibody fragment comprises a heavy chain variable domain (e.g., V H ) and a light chain variable domain (e.g., a V L or V K ).
• the antibody fragment comprises a Fab which comprises a heavy chain variable domain (e.g., V H ) and a light chain variable domain (e.g., a V L or V K ).
• the antibody fragment does not comprise any domains from the Fc region, e.g., does not comprise any CH2 or CH3 domains.
• the antibody fragment is an antibody fragment of, or derived from, any of a variety of antibodies, including, e.g., fully human, humanized or chimeric antibodies.
• the antibody from which the antibody fragment is obtained or derived can be of any of a variety of antibody classes, including, e.g., an IgG1 antibody, an IgG2 antibody, an IgG4 antibody.
• the antibody fragment is obtained or derived from an agonistic antibody, e.g., an agonistic humanized antibody.
• the antibody fragments in the various types of fusion polypeptides may be capable of binding to different antigens, capable of binding the same epitope on an antigen, capable of binding to epitopes that are distinct and non-overlapping on an antigen, or capable of binding to epitopes that are distinct but overlapping on an antigen. 4.
• linkers are used within fusion polypeptides and/or within single-chain molecules such as scFcs.
• the linker is an amino acid linker.
• a linker as employed herein may comprise from about 1 to about 100 amino acid residues, e.g., about 1 to about 70, about 2 to about 70, about 1 to about 30, or about 2 to about 30 amino acid residues.
• the linker comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid residues.
• the linker comprises a glycine-serine sequence, e.g., a (G n S) m sequence (e.g., GGS, GGGS (SEQ ID NO:18), or GGGGS (SEQ ID NO:19) sequence) that is present in at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, or at least 14 copies within the linker.
• G n S m sequence
• GGS GGGS
• SEQ ID NO:19 GGGGS sequence
• provided self-assembled polypeptide complexes comprise (a) a plurality of first fusion polypeptides, each first fusion polypeptide comprising (1) an Fc polypeptide linked to (2) a nanocage monomer or subunit thereof, wherein the Fc polypeptide comprises an Fc chain having one or more mutations relative to a reference Fc chain of the same Ig class, and (b) a plurality of second fusion polypeptides, each second fusion polypeptide comprising (1) an antigen-binding antibody fragment linked to (2) a nanocage monomer or subunit thereof.
• the nanocage monomer is a ferritin monomer
• each fusion polypeptide within the self-assembled polypeptide complex comprises a ferritin light chain or a subunit of a ferritin light chain.
• the self-assembled polypeptide complex does not comprise any ferritin heavy chains, subunits of ferritin heavy chains, or other ferritin components capable of binding to iron or capable of ferroxidase activity.
• the nanocage monomer or subunit thereof is a ferritin monomer subunit, and (a) each first fusion polypeptide comprises a ferritin monomer subunit which is C-half-ferritin and each second fusion polypeptide comprises a ferritin monomer subunit which is N-half-ferritin; or (b) each first fusion polypeptide comprises a ferritin monomer subunit which is N-half ferritin and each second fusion polypeptide comprises a ferritin monomer subunit which is C-half-ferritin.
• the self-assembled polypeptide complex comprises between 24 and 48 fusion polypeptides in total.
• the self-assembled polypeptide complex comprises 24 fusion polypeptides in total. In some embodiments, the self-assembled polypeptide complex comprises more than 24 fusion polypeptides, e.g., at least 26, at least 28, at least 30, at least 32 fusion polypeptides, at least 34 fusion polypeptides, at least 36 fusion polypeptides, at least 38 fusion polypeptides, at least 40 fusion polypeptides, at least 42 fusion polypeptides, at least 44 fusion polypeptides, at least 46 fusion polypeptides, or at least 48 fusion polypeptides in total. In some embodiments, the self-assembled polypeptide complex comprises about 32 fusion polypeptides.
• the self-assembled polypeptide complex comprises at least 4, at least 5, least 6, at least 7, or at least 8 first fusion polypeptides. [0119] In some embodiments, the self-assembled polypeptide complex comprises at least 4, at least 5, least 6, at least 7, or at least 8 second fusion polypeptides. [0120] In some embodiments, the self-assembled polypeptide complex further comprises at least 4, at least 5, least 6, at least 7, at least 8, at least 9, at least 10, least 11, at least 12, at least 13, at least 14, at least 15, or at least 16 third fusion polypeptides.
• the self-assembled polypeptide complex comprises a ratio of approximately 1:1, 11:13, 3:5, 1:2, 7:17, 1:3, 2:7, 5:19, 1:4, 1:5, 1:6, 1:7, 1:8, 1:12, 1:24 of first fusion polypeptides to all other fusion polypeptides.
• a provided self-assembled polypeptide complex when administered to a subject in need thereof, has one or more pharmacokinetic features similar to that of a reference IgG molecule (e.g., an IgG molecule whose class matches the class of an Fc chain within an Fc polypeptide of a first fusion polypeptide within the self-assembled polypeptide complex).
• a reference IgG molecule e.g., an IgG molecule whose class matches the class of an Fc chain within an Fc polypeptide of a first fusion polypeptide within the self-assembled polypeptide complex.
• the ranges for the pharmacokinetic characteristics discussed herein are obtained when the self- assembled polypeptide complex is administered to a human subject.
• the ranges for the pharmacokinetic characteristics discussed herein are obtained when the self-assembled polypeptide complex is administered via a systemic route, e.g., via intravenous or subcutaneous administration.
• a self-assembled polypeptide complex as disclosed herein has a similar half-life to that of reference IgG molecule.
• the reference IgG molecule may be, e.g., an antibody from which the antigen-binding antibody fragment within the second and/or third fusion polypeptide within the self-assembled polypeptide complex is derived.
• the self- assembled polypeptide complex after administration to a subject in need thereof, has a half-life of between about 3 to 35 days, about 3 to about 28 days, about 3 to about 21 days, about 3 to about 14 days, about 3 to about 10 days, about 3 to about 7 days, about 3 to about 5 days, about 5 to about 35 days, about 5 to about 28 days, about 5 to about 21 days, about 5 to about 14 days, about 5 to about 10 days, about 5 to about 7 days, about 7 to about 35 days, about 7 to about 28 days, about 7 to about 21 days, about 7 to about 14 days, about 7 to about 10 days, about 10 to about 35 days, about 10 to about 28 days, about 10 to about 21 days, about 10 to about 14 days, about 14 to about 35 days, about 14 to about 28 days, about 10 to about 21 days, about 10 to about 14 days, about 14 to about 35 days, about 14 to about 28 days, about 10 to about 21 days, about 10 to about 14 days, about 14 to about 35 days, about 14 to about 28 days, about 10 to about 21
• the self-assembled polypeptide complex after administration to a subject in need thereof, has a half-life of at least 3 days, at least 5 days, at least 7 days, at least 10 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, after administration to a subject in need thereof, the self-assembled polypeptide complex is detectable in serum after at least 3 days, at least 5 days, at least 7 days, at least 10 days, at least 14 days, at least 21 days, or at least 28 days.
• a self-assembled polypeptide complex as disclosed herein has a similar bioavailability to that of reference IgG molecule, e.g., an antibody from which the Fab fragment comprised in the self-assembled polypeptide complex is derived.
• the self- assembled polypeptide complex after administration to a subject in need thereof, has an area-under-the-curve (AUC) of between about 10 to about 8000 day ⁇ g/mL, about 10 to about 7000 day ⁇ g/mL, about 10 to about 6000 day ⁇ g/mL, about 10 to about 5000 day ⁇ g/mL, about 10 to about 4000 day ⁇ g/mL, about 10 to about 3000 day ⁇ g/mL, about 10 to about 2500 day ⁇ g/mL, about 10 to about 1000 day ⁇ g/mL, about 10 to about 1500 day ⁇ g/mL, about 10 to about 1000 day ⁇ g/mL, about 10 to about 750 day ⁇ g/mL, about 10 to about 500 day ⁇ g/mL, about 10 to about 400 day ⁇ g/mL, about 10 to about 300 day ⁇ g/mL, about 10 to about 200 day ⁇ g/mL, about 10 to about 100 day ⁇ g/mL, about 10 to about 50 day ⁇ g/mL, about
• AUC area-under
• the self-assembled polypeptide complex after administration to a subject in need thereof, has an AUC of at least 10 day ⁇ g/mL, at least 25 day ⁇ g/mL, at least 50 day ⁇ g/mL, at least 100 day ⁇ g/mL, at least 200 day ⁇ g/mL, at least 300 day ⁇ g/mL, at least 400 day ⁇ g/mL, at least 500 day ⁇ g/mL, at least 750 day ⁇ g/mL, at least 1000 day ⁇ g/mL, at least 1500 day ⁇ g/mL, at least 2000 day ⁇ g/mL, at least 2500 day ⁇ g/mL, at least 3000 day ⁇ g/mL, at least 4000 day ⁇ g/mL, at least 5000 day ⁇ g/mL, at least 6000 day ⁇ g/mL, at least 7000 day ⁇ g/mL, or at least 8000 day ⁇ g/mL.
• a self-assembled polypeptide complex as disclosed herein has a similar bioavailability to that of reference IgG molecule.
• the self-assembled polypeptide complex after administration to a subject in need thereof, has a maximum concentration (C max ) of between about 10 ⁇ g/mL to about 750 mg/mL, about 25 ⁇ g/mL to about 750 mg/mL, about 50 ⁇ g/mL to about 750 mg/mL, about 75 ⁇ g/mL to about 750 mg/mL, about 100 ⁇ g/mL to about 750 mg/mL, about 250 ⁇ g/mL to about 750 mg/mL, about 500 ⁇ g/mL to about 750 mg/mL, about 750 ⁇ g/mL to about 750 mg/mL, about 1 mg/mL to about 750 mg/mL, about 10 mg/mL to about 750 mg/mL, about 25 mg/mL to about
• the self-assembled polypeptide complex after administration to a subject in need thereof , has a maximum concentration (Cmax) of at least 10 ⁇ g/mL, at least 25 ⁇ g/mL, at least 50 ⁇ g/mL, at least 100 ⁇ g/mL, at least 250 ⁇ g/mL, at least 500 ⁇ g/mL, at least 750 ⁇ g/mL, at least 1 mg/mL, at least 10 mg/mL, at least 25 mg/mL, at least 50 mg/mL, at least 75 mg/mL, at least 100 mg/mL, at least 250 mg/mL, at least 500 mg/mL, or at least 750 mg/mL when administered to a subject in need thereof.
• Cmax maximum concentration
• administration of a self-assembled polypeptide complex as disclosed herein to a subject results in an improvement in a clinical outcome or metric in the subject.
• administration of the self-assembled polypeptide complex may inhibit or slow progression of the tumor, e.g., cause regression of the tumor.
• administration of the self-assembled polypeptide complex results in complete regression of the tumor.
• compositions for administration to subjects generally comprise a self-assembled polypeptide complex as disclosed herein. In some embodiments, such compositions further comprise a pharmaceutically acceptable excipient.
• compositions may be formulated for administration for any of a variety of routes of administration, including systemic routes (e.g., oral, inhalation, intranasal, intravenous, intraperitoneal, subcutaneous, or intramuscular administration).
• systemic routes e.g., oral, inhalation, intranasal, intravenous, intraperitoneal, subcutaneous, or intramuscular administration.
• the step of administering results in improvement in one or more clinical outcomes or metrics in the subject.
• the step of administering results in slowing or inhibiting progression of the tumor, e.g., regression of the tumor.
• the step of administering results in complete regression of the tumor.
• DR5-targeting Multabodies comprising a combination of fusion proteins comprising a (1) human ferritin light chain or subunit thereof and (2) a single-chain Fab (scFab) or a single chain Fc-dimer (scFc), fused via a linker, such as a (Gly n -Ser) m amino acid linker as described herein.
• a linker such as a (Gly n -Ser) m amino acid linker as described herein.
• fusion proteins (1) scFab of an anti-DR5 antibody (in this case, conatumumab) fused to the N-terminus of hFTL (aDR5-hFTL, SEQ ID NO:9), (2) scFab of an anti-DR5 antibody fused to the N-terminus of an N-half ferritin (aDR5-N_hFTL, SEQ ID NO:11), and (3) scFc fused to the N-terminus of a C-half ferritin (various scFc-C_hFTL constructs, as described further below) were prepared, mixed at a molar ratio of 2:1:1 and transiently transfected into ExpiCHO-S cells for the production and formation of the DR5- targeting MBs.
• scFab of an anti-DR5 antibody in this case, conatumumab fused to the N-terminus of hFTL (aDR5-hFTL, SEQ ID NO:9)
• the scFc-ferritin fusion proteins comprised wild-type (WT) or engineered IgG1 Fc chains.
• the engineered IgG1 Fc chains contained various combinations of the L234A, L235A, G236R, G237A, P329G, and A330L mutations, as shown in Table 1 below. Numbering in Table 1 is according to the EU numbering scheme. Table 1. Residues at certain positions within IgG1 Fc chains used in Multabodies and corresponding SEQ ID NOs of scFc-C_hFTL constructs [0137] In rows corresponding to sets of engineered Fc chains, residues are only shown at positions that differ from the wild type residue. Example 2.
• Target binding of Multabodies determined by biolayer interferometry [0138] The binding kinetics and affinity of exemplary MBs generated as described in Example 1 to recombinant human DR5 (hDR5), cynomolgus DR5 (cDR5), mouse DR5 (mDR5), and rat DR5 (rDR5) were determined by biolayer interferometry (BLI) using an Octet RED96 instrument.
• hDR5 human DR5
• cDR5 cynomolgus DR5
• mDR5 mouse DR5
• rDR5 rat DR5
• Binding characteristics were determined for (1) conatumumab, a fully human monoclonal IgG1 antibody that binds to DR5, and (2) Cona MB IgG1 LLRAL, a Multabody that includes fusion polypeptides that include a scFc with the “LLRAL” mutations described in Table 1, and which also includes fusion polypeptides that comprise a scFab derived from conatumumab.
• Ni-NTA biosensors were coated with hDR5-His, cDR5-His, mDR5-His, or rDR5-His (extracellular domain of hDR5, cDR5, mDR5, or rDR5 with a C-terminal polyhistidine tag) to reach a signal response of 0.8 nm.
• the coated biosensors were dipped into wells containing serial dilutions of the test MBs (20-10-5-2.5-1.25-0.63 nM) in PBS- 0.02%T-0.01%BSA (PBS supplemented with 0.02% (v/v) Tween 20 and 0.01% (w/v) BSA) for 180 s (association phase) and then into PBS-0.02%T-0.01%BSA for 180 s (dissociation phase). All measurements were performed at 30 °C in PBS-0.02%T-0.01%BSA, pH 7.4, with shaking speed 1000 rpm and monitored in real time.
• Biosensors were regenerated between experiments by applying 10 mM glycine, pH 1.7, for 5 s for four times, followed by recharging with 10 mM NiSO 4 for 1 min.
• Target binding was evaluated based on the maximal association binding response at the end of the association phase, the dissociation rate (koff), and/or the equilibrium dissociation constant (K D ) calculated using a 1:1 fitting model.
• K D equilibrium dissociation constant
• Table 2. Kinetic constants and affinities to target binding of Multabodies determined by BLI Example 3. Binding specificity of Multabodies determined by biolayer interferometry [0142] BLI was employed to assess the non-specific binding of exemplary DR-targeting MBs to related tumor necrosis factor receptor superfamily (TNFRSF) members.
• TNFRSF tumor necrosis factor receptor superfamily
• FIGs.2A, 2B, 2C, 2D, and 2E show representative examples of relevant segments of the resulting sensorgrams. Cona MB IgG1 LLRAL bound DR5 with high specificity and showed no binding to other tested TNFRSF members. Example 4.
• Binding of Multabodies to Fc receptors determined by biolayer interferometry [0145] The binding kinetics and affinities of various DR5-targeting MBs (each comprising different sets of Fc mutations and generated as described in Example 1) to various Fc receptors were determined by BLI. [0146] All MBs tested in this Example contained polypeptides comprising scFabs derived from conatumumab, which binds to DR5. These DR5-targeting MBs (“Cona MB”) also included polypeptides having scFcs with the either wild type Fc chains (IgG1 wt) or Fc chains with a certain combination of mutations (IgG1 LLRAL).
• Binding to the following human, cynomolgus monkey, and mouse Fc receptors were determined: human Fc gamma receptor type I (hFc ⁇ RI), hFc ⁇ RIIa, hFc ⁇ RIIb, hFc ⁇ RIIIa, hFc ⁇ RIIIb, human neonatal Fc receptor (hFcRn), cynomolgus monkey Fc ⁇ RI (cFc ⁇ RI), cFc ⁇ RIIa, cFc ⁇ RIIb, cFc ⁇ RIII, cFcRn, mouse Fc ⁇ RI (mFc ⁇ RI), mFc ⁇ RIIb, mFc ⁇ RIII, mFc ⁇ RIV, and mFcRn.
• human Fc gamma receptor type I hFc ⁇ RI
• hFc ⁇ RIIa human Fc ⁇ RIIa
• hFc ⁇ RIIb hFc ⁇ RIIIa
• FIG.3 shows representative examples of relevant segments of resulting sensorgrams from the FcRn binding studies. All tested MBs bound to human, cynomolgus monkey, and mouse FcRns at pH 6.0 and dissociated from the receptors at pH 7.4. Cona MB IgG1 LLRAL dissociated from human or cynomolgus monkey FcRn at pH 7.4 at a comparable rate to Cona MB IgG1 WT. Table 3. Kinetic constants and affinities to Fc ⁇ Rs of Multabodies determined by BLI
• Example 5 Assessment of in vitro tumor cell cytotoxicity [0151] The cytotoxicity of exemplary DR5-targeting MBs (generated as described in Example 1) was evaluated using different tumor cell lines. Cona MB IgG1 wt and Cona MB IgG1 LLRAL were tested on COLO 205 (human colon carcinoma), HCT-15 (human colon carcinoma), NCI-H2122 (human lung carcinoma), SNU-5 (human gastric carcinoma), Capan- 1 (human pancreatic carcinoma), MDA-MB-231 (invasive ductal carcinoma), BxPC-3 (human pancreatic carcinoma), and NCI-H2228 (human lung carcinoma) cell lines.
• COLO 205 human colon carcinoma
• HCT-15 human colon carcinoma
• NCI-H2122 human lung carcinoma
• SNU-5 human gastric carcinoma
• Capan- 1 human pancreatic carcinoma
• MDA-MB-231 invasive ductal carcinoma
• BxPC-3 human pancreatic carcinoma
• NCI-H2228 human lung carcinoma
• Tumor cell lines were seeded at 5000 cells per well in a 96-well plate and incubated overnight to facilitate attachment. The next day, cells were treated with serial dilutions of DR5-targeting MBs or anti-DR5 (conatumumab) and incubated for 24 h at 37 °C. Cell viability was measured using the CellTiter-Glo Luminescence Cell Viability Assay (Promega), according to the manufacturer’s instruction. Briefly, assay reagent (100 ⁇ L) was added to 100 ⁇ L cells at room temperature, mixed using a plate shaker at 500 rpm for 2 min, and incubated at room temperature for 10 min.
• Luminescent signals were read using the Synergy Neo2 Multi-Mode Assay Microplate Reader (BioTek Instruments). [0153] FIG.4 shows results from these experiments. In FIG.4, the percentage of viable cells (compared to vehicle-treated tumor cells) was plotted on the y-axis versus the test molecule concentration on the x-axis. The data were fitted using Prism 9.1.2 software (GraphPad) with nonlinear regression (log inhibitor vs. response, variable slope, 4 parameters). Table 4 provides the resulting IC50 values. Both of the tested DR5-targeting MBs (Cona MB IgG1 wt and Cona MB IgG1 LLRAL) were capable of inducing cytotoxicity of human cancer cells lines. On the other hand, conatumumab—an IgG1 antibody—did not induce, or very poorly induced, tumor cell cytotoxicity. Table 4. Assessment of tumor cell cytotoxicity
• Example 6 Pharmacokinetics of Multabodies in mice [0154]
• the pharmacokinetics (PK) of exemplary DR5-targeting MBs generated as described in Example 1 (Cona MB IgG1 LLRAL and conatumumab) were analyzed in 8- week old female BALB/c SCID mice (Jackson Labs).
• mice were injected with 200 ⁇ L test molecule at 5 mg/kg on day 9, followed by a second injection of 200 ⁇ L test molecule at 5 mg/kg 96 h after.50- 100 ⁇ L blood samples were collected 3 h, 24 h, 48 h, 72 h, and 96 h after the first dose and 3 h, 24 h, 48 h, 72 h, 5 days, 7 days, and 14 days after the second dose.
• Blood samples were collected from the saphenous vein into heparin-coated tubes and finger-vortexed to ensure mixing.
• Plasma samples were diluted in PBS-0.05%T-0.5%BSA (PBS supplemented with 0.05% (v/v) Tween-20 and 0.5% (w/v) BSA), added to wells, and incubated for 1 h at room temperature and a shaking frequency of 500 rpm, followed by another wash step with PBS-0.05%T. Bound molecules were detected by incubation with 1:10000 diluted goat polyclonal anti-human Fc-HRP secondary antibody (Jackson Immunoresearch).
• FIG.5A is a schematic illustrating the design of these pharmacokinetic studies.
• FIG.5B shows plots of the plasma concentration over time in a single-dose PK study for Cona MB IgG1 wt, Cona MB IgG1 LLRAL, and conatumumab (“Cona”).
• Table 5 presents a summary of calculated half-lives.
• Cona MB IgG1 LLRAL showed significantly enhanced PK properties compared to Cona MB IgG1 wt.
• the plasma concentrations of Cona MB IgG1 LLRAL remained comparable to that of conatumumab.
• FIG.5C shows plots of plasma concentration over time in a multi-dose PK study for Cona MB IgG1 LLRAL and conatumumab. Table 5. Half-lives in mice after a single dose Example 7.
• Therapeutic effect of DR5-targeting Multabodies in a xenograft mouse model [0162] The therapeutic effect of exemplary Multabodies was evaluated in a colon cancer xenograft model.
• FIG.6A shows a schematic illustrating the study design of the in vivo efficacy study.
• FIGs.6B-6G are plots that depict tumor volumes of mice in various groups.
• the plots in FIGs.6B and 6D-6G show tumor volumes over time, and the plot in FIG.6C shows the tumor volume at day 88 after treatment initiation.
• Treatment with Cona MB IgG1 LLRAL once or twice weekly significantly inhibited the growth of large established tumors, suggesting that Cona MB IgG1 LLRAL was able to penetrate tumors even of large size.
• FIG.6H is a plot showing the concentrations of test molecules in plasma (y-axis) as a function of the time after the first dose (x-axis).
• the pharmacokinetic profile of Cona MB IgG1 LLRAL as observed in the COLO205 colon cancer mouse model is similar to that observed in the multi-dose PK study described in Example 6. (See FIG.5B).
• Dose range efficacy of DR5-targeting Multabodies in a xenograft mouse model [0167] The dose range efficacy of Cona IgG1 MB LLRAL was also explored in the same colon cancer xenograft model used in Example 6. [0168] 5 x 10 6 COLO 205 cells were injected subcutaneously in the flank of Balb/c SCID mice. Tumors were allowed to grow to an average size of 200 mm 3 . Mice were sorted into one of five groups (vehicle or Cona MB IgG1 LLRAL at 0.1 mg/kg, 0.25 mg/kg, 1 mg/kg, or 5 mg/kg per dose) such that the mean tumor volumes were equal across the groups.
• FIG.7A is a plot that depicts tumor volumes of mice in various groups over time following the first dose. “MB” indicates the Cona MB IgG1 LLRAL group.
• FIGs.7B-7F show the tumor volumes of individual mice within the vehicle (FIG.7B) and 5 mg/kg, 1 mg/kg, 0.25 mg/kg, and 0.1 mg/kg Cona MB IgG1 LLRAL treatment (FIG.7C, FIG.7D, FIG.7E, and FIG.7F, respectively) groups.
• FIG.7A is a plot that depicts the amount of Cona MB IgG1 LLRAL detectable in blood samples collected at various timepoints after the first dose was administered.
• Cona MB IgG1 LLRAL was detectable in the plasma at all time points tested in the 0.1 mg/kg, 0.25 mg/kg, 1 mg/kg/ and 5 mg/kg Cona MB IgG1 LLRAL treatment groups, with the pharmacokinetics appearing linear in all dose groups.
• These results demonstrate that Cona MB IgG1 LLRAL exhibited therapeutic efficacy at multiple doses tested, including comparable efficacy at a dose level that was five- fold lower than that tested in Example 6. However, whereas complete tumor regression was observed at the 5 mg/kg dose level, some tumor regrowth was observed when the dose level was lowered to 1 mg/kg.
• Example 9
• Exemplary Multabodies generated as described in Example 1 were evaluated for their ability to penetrate large tumors and induce apoptosis in a colon xenograft model.
• 5 x 10 6 COLO 205 cells were injected subcutaneously in the flank of Balb/c SCID mice. Tumors were allowed to an average size of 500 mm 3 . Tumor volume was measured twice weekly using calipers. Mice were randomly assigned to a vehicle or treatment groups such that the average tumor size was the same across the two groups, about 500 mm 3 in each group.
• FIG.8 depicts a schematic and timeline for these experiments.
• Tumors were fixed in formalin, embedded in paraffin, and sectioned. Tumor sections were stained immunohistochemically for cleaved caspase-3, a marker of apoptosis.
• FIGs.9A and 9C vehicle- treated mice
• FIGs.9B and 9D Cona MB IgG1 LLRAL-treated mice.
• tissue sections from Cona MB IgG1 LLRAL-treated mice contained a large proportion of apoptotic cells throughout the tumor including deep within the core of the tumor, away from the tumor margin (see stained cells in FIGs.9B and 9D).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Nanotechnology (AREA)
• Transplantation (AREA)
• Cell Biology (AREA)
• Toxicology (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Peptides Or Proteins (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=85506121

Family Applications (1)

Country Status (9)

Citations (2)

• 2022
  • 2022-09-13 MX MX2024003140A patent/MX2024003140A/es unknown
  • 2022-09-13 US US18/691,267 patent/US20240400704A1/en active Pending
  • 2022-09-13 AU AU2022343032A patent/AU2022343032A1/en active Pending
  • 2022-09-13 CA CA3231173A patent/CA3231173A1/en active Pending
  • 2022-09-13 EP EP22865992.6A patent/EP4402179A4/en active Pending
  • 2022-09-13 WO PCT/CA2022/051360 patent/WO2023035083A1/en not_active Ceased
  • 2022-09-13 JP JP2024516396A patent/JP2024533487A/ja active Pending
  • 2022-09-13 KR KR1020247011820A patent/KR20240102943A/ko active Pending
  • 2022-09-13 CN CN202280066146.9A patent/CN118488971A/zh active Pending

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events